introduct
therapeut
plasma
exchang
tpe
firstlin
treatment
acut
thrombot
thrombocytopen
purpura
ttp
methylen
blueplasma
mbp
use
year
efficaci
set
remain
controversi
patient
method
compar
analysi
experi
two
centr
differ
plasma
product
evalu
efficaci
ttp
one
centr
use
quarantin
plasma
qp
mbp
perform
retrospect
longitudin
studi
analys
clinic
file
ttp
patient
data
evalu
period
durat
treatment
transfus
paramet
medic
record
laboratori
test
concomit
medic
surviv
rate
assess
everi
episod
result
studi
period
new
case
treat
qp
mbp
respect
signific
differ
mean
number
tpe
process
day
elaps
diagnosi
tpe
plasma
volum
transfus
qp
tpe
episod
treatment
significantli
associ
increas
time
recoveri
compar
mbp
episod
treatment
p
conclus
mbp
effect
qp
treatment
ttp
patient
sinc
recoveri
favour
mbp
use
consid
mbp
remain
suitabl
altern
treat
ttp
patient
thrombot
thrombocytopen
purpura
ttp
rare
hematolog
diseas
initi
describ
moschcowitz
incid
low
less
casesmillionyear
seriou
lifethreaten
disord
character
sever
thrombocytopenia
typic
plateletsl
neg
direct
antiglobulin
test
microangiopath
haemolyt
anaemia
multiviscer
ischem
symptom
usual
neurolog
chang
renal
impair
fever
appar
caus
twice
frequent
women
men
happen
mostli
adulthood
tendenc
recurr
relaps
often
associ
clinic
condit
found
half
case
ttp
diagnos
bacteri
viral
infect
autoimmun
diseas
associ
drug
ttp
consequ
sever
function
defici
activ
von
willebrand
factor
vwf
disintegrin
metalloproteas
thrombospondin
type
motif
member
either
congenit
acquir
associ
presenc
inhibitori
antibodi
result
ultralarg
vwf
multim
cleav
accumul
bloodstream
promot
platelet
plt
aggreg
intravascular
thrombosi
pathophysiolog
condit
addit
factor
trigger
clinic
syndrom
ttp
high
mortal
rate
systemat
implement
therapeut
plasma
exchang
tpe
although
mortal
drastic
reduc
ttp
still
fatal
outcom
rate
tpe
effect
safe
treatment
consid
firstlin
therapi
acut
ttp
tpe
remov
antibodi
inhibit
suppli
fresh
concomit
steroid
rituximab
given
depend
clinic
context
apart
quarantin
fresh
frozen
plasma
qp
sever
pathogenreduc
plasma
product
avail
tabl
supplier
use
solventdetergenttr
pool
plasma
octaplaslg
octapharma
other
use
photosensit
light
amotosalen
ultraviolet
light
intercept
plasma
ceru
methylen
blue
mb
visibl
light
theraflex
mbplasma
macopharma
current
use
demonstr
therapeut
efficaci
safeti
ttp
patient
although
level
mblight
treatment
normal
similar
pathogenreduc
plasma
qp
use
mb
remain
controversi
author
suggest
less
effect
term
volum
plasma
requir
qp
ttp
patient
argu
tpe
session
larger
amount
mbplasma
requir
achiev
ttp
remiss
j
u
r
n
l
p
r
e
p
r
f
mblight
photodynam
pathogen
inactiv
procedur
singl
unit
fresh
frozen
plasma
ffp
theraflex
mbplasma
system
use
photosensit
agent
mb
visibl
light
nm
intercal
rnadna
backbon
pathogen
genom
mani
biolog
effect
mb
close
associ
uniqu
physicochem
properti
includ
redox
characterist
ionic
charg
light
spectrum
characterist
photosensitis
mb
two
differ
mechan
action
excit
light
induc
singlet
triplet
stage
molecul
transfer
energi
either
electron
type
mechan
energi
type
ii
mechan
type
mechan
lead
format
hydroxyl
radic
lipid
hydroperoxid
type
ii
mechan
proce
singlet
oxygen
result
mainli
breakag
nucleic
acid
mostli
guanosin
site
lead
oxid
destruct
viral
nucleic
acid
strand
breakag
prevent
viral
replic
especi
lipid
peroxid
induc
mb
photosensit
detriment
effect
membran
integr
lead
loss
fluiditi
alter
function
sever
ion
channel
receptor
transport
theraflex
mbplasma
system
proven
highli
effect
inactiv
lipidenvelop
virus
human
immunodefici
viru
hiv
hepat
b
c
virus
nonenvelop
virus
parvoviru
arbovirus
like
west
nile
viru
dengu
zika
chikungunya
emerg
virus
middl
east
respiratori
syndrom
coronaviru
ebola
recent
sever
acut
respiratori
syndrom
coronaviru
sarscov
crimeancongo
haemorrhag
fever
viru
nipah
viru
effect
inactiv
ampl
clinic
experi
use
product
shed
light
therapeut
impact
mblight
safeti
efficaci
plasma
awar
difficulti
develop
prospect
studi
two
neighbour
region
northern
spain
asturia
cantabria
fulfil
sever
favour
condit
develop
longitudin
retrospect
studi
reduc
far
possibl
bia
select
nonhomogen
popul
commun
share
common
characterist
proxim
geographi
climat
resourc
histori
main
differ
purpos
first
one
use
mbplasma
standard
treat
ttp
patient
second
one
use
qp
retrospect
analysi
began
realworld
data
clinic
health
record
patient
diagnos
acut
idiopath
ttp
treat
tpe
two
univers
demograph
paramet
collect
patient
clinic
record
diagnosi
tpe
treatment
initi
complet
date
time
diagnosi
start
tpe
day
record
everi
episod
well
process
date
transfus
plasma
volum
ml
plt
count
x
l
ldh
level
iul
clinic
inform
laboratori
test
diagnosi
concomit
medic
surviv
rate
also
obtain
direct
coomb
test
haptoglobin
level
mgdl
activ
inhibitori
autoantibodi
collagenbind
affin
method
gather
medic
record
avail
compar
surviv
rate
caus
death
analys
safeti
outcom
evalu
total
plasma
volum
transfus
tpe
treatment
period
includ
comparison
analysi
criteria
claim
complet
respons
tpe
treatment
combin
full
clinic
recoveri
plt
count
return
normal
x
pltl
serum
ldh
level
revert
within
normal
rang
iul
least
two
consecut
day
assess
group
label
qp
group
correspond
medic
record
patient
evalu
cantabria
treat
quarantin
plasma
qp
ffp
produc
banco
de
sangr
tejido
de
cantabria
liencr
spain
accord
council
europ
recommend
keiter
mbp
group
includ
document
patient
asturia
treat
theraflex
mb
system
inactiv
plasma
mblightbas
theraflex
mbplasma
pathogen
reduct
system
macopharma
mouvaux
franc
suppli
centro
comunitario
de
sangr
tejido
de
asturia
oviedo
spain
follow
manufactur
specif
plasma
unit
obtain
volunt
donor
either
apheresi
whole
blood
quarantin
plasma
store
frozen
donor
return
second
time
least
four
month
initi
donat
viral
serolog
marker
still
neg
transfus
softwar
lift
quarantin
plasma
pass
avail
stock
j
u
r
n
l
p
r
e
p
r
f
theraflex
mbplasma
system
consist
plasmaflex
leukocyt
deplet
filter
elimin
intracellular
virus
remov
residu
cell
present
plasma
mb
pill
dissolv
filter
plasma
product
illumin
option
blueflex
filter
attach
bag
system
remov
residu
mb
photoproduct
centr
use
cobe
spectra
system
terumo
bct
usa
tpe
run
therapeut
autom
plasmapheresi
protocol
treatment
session
aim
exchang
one
blood
volum
process
blood
anticoagul
acda
vv
came
dispos
kit
anticoagul
revers
outflow
line
equimolar
calcium
magnesium
chlorid
continu
variabl
repres
descript
statist
paramet
number
case
arithmet
mean
median
standard
deviat
sd
qualit
variabl
characteris
number
observ
categori
absolut
frequenc
rel
frequenc
percentag
compar
analysi
group
good
fit
gaussian
distribut
quantit
paramet
verifi
group
subgroup
use
kolmogorovsmirnov
test
homogen
group
treat
qp
mbp
subgroup
test
baselin
characterist
rest
paramet
evalu
use
student
ttest
mannwhitney
test
independ
sampl
direct
qp
valu
minu
mbp
valu
calcul
confid
interv
ci
differ
mean
standard
error
differ
se
quantit
paramet
pearson
chisquar
test
fisher
exact
test
use
qualit
paramet
compar
test
perform
consid
statist
signific
probabl
error
p
first
relaps
variabl
taken
account
compar
demograph
inform
total
new
case
record
qp
mbp
respect
one
patient
qp
group
relaps
comparison
two
patient
mbp
p
therefor
total
analysi
obtain
evolut
episod
ttp
mbp
episod
qp
group
mean
age
year
n
median
year
age
rang
five
year
sixteen
patient
women
tpe
treatment
start
day
diagnosi
day
day
episod
treat
tpe
averag
patient
requir
tpe
process
median
tpe
rang
tpe
time
diagnosi
start
tpe
day
averag
median
day
rang
day
tpe
treatment
last
day
median
day
rang
one
day
patient
given
corticoid
perprotocol
concomit
medic
usual
rituximab
statist
differ
qp
mbp
treatment
group
concern
age
year
year
respect
p
gender
femal
respect
p
episod
group
similar
clinic
laboratori
data
tabl
mbp
group
higher
lymphocyt
monocyt
count
qp
group
p
p
respect
signific
differ
observ
mean
number
tpe
process
day
elaps
diagnosi
start
tpe
total
plasma
volum
transfus
j
u
r
n
l
p
r
e
p
r
f
episod
qp
mbp
group
total
tpe
process
qp
mbp
took
place
period
evalu
two
centr
compar
tpe
process
although
paramet
collect
process
differ
qp
mbp
group
transfus
plasma
volum
plt
count
ldh
level
tabl
compar
tpe
day
treatment
live
deceas
patient
nonsignific
differ
found
patient
die
day
n
surviv
day
n
p
howev
none
patient
die
receiv
tpe
treatment
day
wherea
surviv
treat
longer
time
p
compar
evalu
mean
volum
plasma
transfus
process
result
signific
differ
patient
die
ml
n
ml
n
plt
count
significantli
lower
patient
die
x
pltl
n
compar
x
pltl
n
x
pltl
p
ci
x
pltl
ldh
level
significantli
higher
patient
die
iul
n
compar
iul
n
iul
p
ci
iul
signific
differ
present
comparison
patient
surviv
patient
die
evalu
period
separ
assess
made
subgroup
patient
surviv
surviv
patient
group
none
document
sequela
nine
treat
qp
mbp
group
significantli
differ
regard
age
year
respect
p
gender
vs
femal
respect
p
anaem
syndrom
cn
involv
hemorrhag
diathesi
clinic
manifest
significantli
differ
group
either
data
shown
need
concomit
medic
also
significantli
differ
tpe
group
regard
clinic
laboratori
data
episod
treatment
group
homogen
data
shown
except
level
lymphocyt
monocyt
remain
significantli
higher
group
treat
mbp
p
p
respect
signific
differ
observ
mean
number
tpe
process
day
elaps
diagnosi
start
tpe
total
plasma
volum
transfus
episod
qp
mbp
group
tabl
surviv
analysi
qp
tpe
episod
significantli
associ
increas
time
recoveri
ttp
episod
compar
mbp
treatment
p
estim
median
day
treatment
qp
day
mbp
group
besid
estim
averag
day
treatment
day
ci
day
qp
group
day
ci
day
mbp
group
detect
episod
treat
qp
took
longer
day
contrast
none
mbp
group
exceed
day
p
process
transfus
plasma
volum
plt
count
ldh
level
tabl
show
statist
differ
qp
mbp
subgroup
patient
surviv
acut
ttp
event
period
studi
assess
efficaci
safeti
mb
pathogeninactiv
plasma
compar
quarantin
ffp
standard
tpe
patient
acut
ttp
two
experienc
centr
follow
tpe
protocol
chosen
geograph
proxim
similar
popul
characterist
avoid
environment
extern
differ
group
patient
safeguard
reliabl
extern
valid
find
signific
differ
tpe
group
neither
demograph
clinic
biochem
haematolog
paramet
therapeut
variabl
heal
process
leucocyt
count
similar
lymphocyt
monocyt
count
significantli
higher
mbp
group
differ
could
show
differ
kind
immun
respons
acut
phase
ttp
defici
accept
main
caus
idiopath
ttp
caus
lymphocyt
macrophag
activ
suggest
differ
found
regard
tpe
treatment
two
compar
group
even
though
time
recoveri
longer
qp
group
impact
outcom
found
process
byprocess
evalu
show
tpe
treatment
prove
differ
two
group
regard
plasma
volum
transfus
platelet
count
ldh
level
regard
remiss
rate
three
patient
die
short
period
qp
treatment
patient
receiv
plasma
volum
show
lower
plt
count
higher
ldh
level
diagnos
surviv
death
record
mbp
group
avoid
bia
due
mortal
observ
qp
group
could
influenc
studi
result
rerun
analysi
cull
dead
patient
differ
found
compar
process
two
tpe
treatment
group
qp
patient
still
requir
day
tpe
treatment
recov
compar
mbp
treatment
result
disput
previou
report
inferior
efficaci
safeti
mb
compar
qp
believ
could
aris
popul
studi
statist
tool
use
one
retrospect
sequenti
studi
compar
qp
mbp
ttp
patient
show
inferior
result
mb
term
number
tpe
process
durat
hospitalis
studi
design
unbalanc
qp
group
n
mbp
group
n
collect
differ
period
year
qp
group
less
year
mbp
group
kind
design
low
statist
power
also
reduc
likelihood
statist
signific
result
reflect
true
effect
besid
ttprelat
death
happen
day
diagnosi
qp
group
day
mbp
group
therefor
qp
group
receiv
fewer
plasma
unit
fewer
episod
hospitalis
time
much
shorter
small
sampl
extrem
valu
may
lead
bia
howev
result
studi
reach
statist
signific
comparison
j
u
r
n
l
p
r
e
p
r
f
number
tpe
process
durat
hospitalis
p
p
respect
remov
analysi
three
patient
die
complet
remiss
rate
qp
mbp
respect
significantli
differ
p
retrospect
studi
reach
similar
conclus
studi
compar
ttp
episod
patient
analysi
approach
base
episod
potenti
caus
mislead
result
age
gender
recurr
mortal
rate
calcul
take
consider
episod
instead
patient
withinsubject
serial
depend
episod
recurr
mortal
result
method
mislead
interpret
data
analysi
besid
odd
ratio
betacoeffici
provid
multivari
logist
regress
model
continu
data
day
elaps
start
ttp
begin
tpe
volum
plasma
replac
first
day
divid
subject
categori
way
cutoff
tend
arbitrari
part
inform
lost
eventu
mbp
inferior
qp
total
plasma
volum
exchang
episod
p
remiss
rate
show
signific
differ
p
subsequ
multicentr
prospect
studi
deduc
mbp
associ
wors
outcom
episod
idiopath
ttp
base
remiss
statu
day
treatment
primari
endpoint
studi
compar
ttp
episod
treat
mbp
qp
studi
approach
base
episod
analysi
equat
episod
patient
potenti
caus
mislead
result
age
gender
remiss
mortal
rate
assess
consid
episod
instead
patient
coher
remiss
defin
respons
eventu
last
longer
day
withdraw
tpe
therapi
inconsist
primari
endpoint
clear
rational
definit
evidencebas
explan
given
besid
homogen
analysi
carri
centr
mannwhitney
test
use
meaning
given
sampl
size
larg
enough
tpe
group
use
parametr
test
moreov
variabl
categoris
arbitrarili
irwin
mcclelland
address
misconcept
perhap
median
split
good
idea
predictor
variabl
remark
skew
instead
normal
distribut
even
situat
split
data
bring
mislead
result
confus
analysi
result
studi
likewis
estim
logist
model
requir
basic
assumpt
met
logist
regress
includ
independ
error
linear
logit
continu
variabl
absenc
multicollinear
lack
strongli
influenti
outlier
mention
prospect
studi
besid
result
logist
regress
j
u
r
n
l
p
r
e
p
r
f
model
assess
use
goodnessoffit
measur
shown
reach
definit
conclus
model
intern
valid
formal
quantifi
ie
replic
within
data
set
extern
valid
ie
generaliz
beyond
current
sampl
comment
analysi
surviv
analysi
found
evalu
evolut
patient
eventu
remiss
achiev
episod
mbp
qp
respect
notwithstand
respons
day
treatment
also
assess
trial
found
signific
differ
mbp
qp
group
respect
p
limit
studi
main
one
inform
gather
retrospect
number
event
small
show
low
incid
ttp
also
reduc
confid
studi
find
convers
think
longitudin
analysi
two
differ
plasma
larg
use
routin
two
differ
transfus
site
may
clear
manag
ttp
help
strengthen
experi
tpe
altern
unfortun
activ
avail
patient
firstlin
treatment
frequent
set
emerg
base
clinic
inform
howev
sever
function
defici
requir
plasma
qualiti
maintain
level
enzym
restor
miss
activ
idiopath
ttp
sever
studi
shown
mbp
retain
similar
level
compar
fresh
frozen
plasma
maintain
hemostat
properti
viral
inactiv
plasma
solventdeterg
plasma
pool
proven
effect
tpe
treatment
howev
markedli
reduc
level
function
protein
activ
may
predispos
develop
venou
thrombosi
particularli
extens
repeat
tpe
patient
undergo
liver
transplant
patient
sever
liver
diseas
known
coagulopathi
scarc
inform
advers
event
clinic
record
made
imposs
perform
thorough
assess
incid
advers
event
ae
detect
event
consid
mild
requir
treatment
interrupt
patient
except
one
patient
mbp
group
present
nonfat
acut
pulmonari
oedema
author
suggest
reduc
risk
ae
mbp
compar
qp
markedli
allerg
reaction
case
thu
pathogen
inactiv
plasma
associ
fewer
allerg
reaction
febril
nonhaemolyt
reaction
transfus
circulatori
overload
taco
hypotens
reaction
untreat
plasma
found
physiopatholog
base
qp
associ
higher
death
rate
probabl
ascertain
proteom
metabolom
studi
perhap
differ
plasma
j
u
r
n
l
p
r
e
p
r
f
microvesicl
qp
mbp
could
play
role
shown
interfer
hemostasi
conclus
realworld
studi
found
mbp
qp
effect
safe
treatment
strategi
idiopath
ttp
patient
found
differ
mbp
qp
term
number
tpe
process
requir
volum
total
plasma
transfus
nevertheless
find
studi
favour
patient
treat
mbp
sinc
qp
tpe
episod
significantli
associ
increas
number
day
treatment
safeti
concern
includ
death
risk
furthermor
consid
import
analys
data
care
context
environ
studi
tabl
tabl
plasma
product
use
ttp
treatment
clinic
laboratori
test
diagnosi
tpe
group
base
number
episod
